Latest News
Acumen Pharmaceuticals begins open-label extension of Phase 2 Alzheimer's study
17 November 2025 - US-based clinical-stage biopharmaceutical company Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), which is developing a therapeutic targeting soluble amyloid beta oligomers for Alzheimer's disease, said on Monday that the first p...
Incyte receives positive CHMP opinion for Minjuvi in relapsed or refractory follicular lymphoma
17 November 2025 - Biopharmaceutical company Incyte (Nasdaq:INCY) announced on Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Minjuvi (tafa...
Henlius and Organon secure first US approval for pertuzumab biosimilar POHERDY
17 November 2025 - China-based biopharmaceutical company Shanghai Henlius Biotech Inc (HK:2696) and US healthcare company Organon (NYSE:OGN) announced on Monday that the US Food and Drug Administration (FDA) has approved POHERDY (pertuzumab-dpzb) 420...
BioInvent secures EMA positive opinion for Orphan Drug Designation of BI-1808 in CTCL
17 November 2025 - Swedish biotech company BioInvent International AB (STO:BINV) announced on Monday that the European Medicines Agency's Committee for Orphan Medicinal Products has issued a positive opinion recommending Orphan Drug Designation ...
IXICO wins GBP3.5m global Phase 3 Huntington's Disease trial contract
17 November 2025 - IXICO plc (AIM:IXI), a provider of neuroscience precision medicine and biomarker analytics, announced on Monday that it has secured a global Phase 3 clinical trial imaging contract worth more than GBP3.5m over four years with a mul...